Venetoclax: all 546 studies that test it

Page 5 of 6. Open to participants first (240), then studies with results posted, then the rest; newest registration first within each.

• Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
• A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)TerminatedNCT04755244Phase 1
• Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT04754035Phase 2
• Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT04746235Phase 2
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
• Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)CompletedNCT04666649Phase 1
• Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Active, not recruitingNCT04657081Phase 1/2
• Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04655755Phase 1/2
• CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.Active, not recruitingNCT04639362Phase 2
• Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Active, not recruitingNCT04608318Phase 3
• Copanlisib Plus Venetoclax in R/R DLBCLActive, not recruitingNCT04572763Phase 1/2
• Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
• Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaTerminatedNCT04550442Phase 1/2
• Venetoclax and Irinotecan in Relapsed/Refractory SCLCWithdrawnNCT04543916Phase 1/2
• Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
• Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid LeukemiaCompletedNCT04512105Phase 1
• A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)CompletedNCT04509622Phase 3
• Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on VenetoclaxActive, not recruitingNCT04501939Phase 2
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCTActive, not recruitingNCT04476199Phase 2
• Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT04450173Phase 2
• The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT04447768Phase 2
• An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentActive, not recruitingNCT04447716Phase 1
• Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With VenetoclaxActive, not recruitingNCT04419519Phase 2
• A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaActive, not recruitingNCT04416451Phase 2
• Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeActive, not recruitingNCT04401748Phase 3
• IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMMLCompletedNCT04372433Phase 1
• Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)CompletedNCT04330820Phase 1/2
• Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
• A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor TherapyTerminatedNCT04274933Phase 1
• A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionTerminatedNCT04274907Phase 1
• Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity ScreeningCompletedNCT04267081Phase 2
• Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
• Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaTerminatedNCT04172844Phase 1
• A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)CompletedNCT04171791Phase 1
• Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT04161248Early Phase 1
• Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromeTerminatedNCT04160052Phase 1/2
• Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingActive, not recruitingNCT04128501Phase 2
• Study of Enasidenib and Venetoclax in IDH2-Mutated Blood CancersTerminatedNCT04092179Phase 1/2
• IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaActive, not recruitingNCT04086264Phase 1/2
• ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationActive, not recruitingNCT04082897Phase 2
• Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS LymphomaTerminatedNCT04073147Phase 1
• AZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionTerminatedNCT04062266Phase 2
• A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AMLCompletedNCT04038437Phase 1
• CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSCompletedNCT04017546Phase 1
• Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic LeukemiaCompletedNCT04010968Phase 2
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasActive, not recruitingNCT03984448Phase 2/3
• Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaActive, not recruitingNCT03980171Phase 1/2
• Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedNCT03969446Phase 1
• Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic MalignanciesCompletedNCT03955783Phase 1
• Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT03946878Phase 2
• Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceWithdrawnNCT03943342Phase 2
• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT03940352Phase 1
• Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML PatientsWithdrawnNCT03932318Phase 1/2
• Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerActive, not recruitingNCT03900884Phase 1
• Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.TerminatedNCT03886649Phase 1
• Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK InhibitorWithdrawnNCT03884972Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
• Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnNCT03856112Phase 1/2
• Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid LeukemiaActive, not recruitingNCT03844815Phase 1
• An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
• Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
• Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)Active, not recruitingNCT03824483Phase 2
• Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic LeukemiaTerminatedNCT03808610Phase 1/2
• A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesTerminatedNCT03797261Phase 1
• Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
• A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
• Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage AActive, not recruitingNCT03766763Phase 2
• Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
• Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03751436Phase 1
• CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLCompletedNCT03739554Phase 1
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaCompletedNCT03713580Phase 1
• Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AMLActive, not recruitingNCT03709758Phase 1
• Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLTerminatedNCT03708003Phase 2
• Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT03701321Phase 1/2
• Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic LeukemiaActive, not recruitingNCT03701282Phase 3
• Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.CompletedNCT03672695Phase 1
• A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03625505Phase 1
• Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
• Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCLCompletedNCT03567876Phase 2
• Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaTerminatedNCT03552692Phase 2
• A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Phase 3
• Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsActive, not recruitingNCT03513562Phase 2
• Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell LymphomaStatus unknownNCT03505944Phase 1/2
• Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)CompletedNCT03485547Phase 1
• A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03484520Phase 1
• A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLLActive, not recruitingNCT03467867Phase 2
• Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
• Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid LeukemiaCompletedNCT03455504Phase 2
• A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441555Phase 1
• Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent IbrutinibActive, not recruitingNCT03422393Phase 1
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeTerminatedNCT03404193Phase 2
• Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaCompletedNCT03399539Phase 1
• Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedNCT03379051Phase 1/2
• A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedNCT03357627Phase 1
• This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxWithdrawnNCT03343678Phase 1
• Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLActive, not recruitingNCT03319901Phase 1/2

← Venetoclax overview